What is the Watchman Device?
The Watchman is a percutaneous left atrial appendage (LAA) closure device designed to prevent stroke in patients with atrial fibrillation by mechanically occluding the LAA, which is the source of approximately 90% of thrombi in non-valvular AF. 1, 2
Device Structure and Mechanism
The Watchman consists of a self-expanding nitinol cage covered with a polyethylene membrane, with fixation barbs that anchor it within the LAA 3. It is deployed percutaneously via transseptal puncture under combined fluoroscopic and echocardiographic guidance 4.
Clinical Indication and Evidence Base
The device was evaluated in two major randomized trials—PROTECT AF and PREVAIL—comparing it to warfarin in patients with non-valvular AF at increased stroke risk 1, 2. The device demonstrated non-inferiority to warfarin for preventing stroke, systemic embolism, and cardiovascular death, with significantly fewer hemorrhagic strokes but a trend toward more ischemic strokes (particularly periprocedural). 2
Key Efficacy Data:
- Network meta-analysis showed stroke/systemic embolism reduction (OR 0.35; 95% CI 0.16-0.80) compared to placebo 1
- Hemorrhagic stroke reduction was substantial (RR 0.09; 95% CI 0-0.45) 5
- When periprocedural events were excluded, ischemic stroke differences were not significant 2
Current Guideline Recommendations
The 2019 AHA/ACC/HRS guidelines give percutaneous LAA occlusion a Class IIb recommendation (may be considered) for patients with AF at increased stroke risk who have contraindications to long-term oral anticoagulation. 2
The 2018 CHEST guidelines suggest LAA occlusion only in patients with absolute contraindications to oral anticoagulation (weak recommendation, low quality evidence) 1.
Important Regulatory Nuance:
There is a critical difference between FDA and CMS approval 2:
- FDA approval: Restricted to patients suitable for long-term warfarin but seeking a non-pharmacological alternative
- CMS approval: For patients suitable for short-term warfarin but unable to take long-term anticoagulation (requires CHADS₂ ≥2 or CHA₂DS₂-VASc ≥3)
Safety Profile and Complications
Periprocedural Risks:
- Overall adverse safety event rate: 4.4% 1
- Serious pericardial effusions requiring drainage: 7.1% in first 3 patients per site, decreasing to 4.4% with experience 1
- Procedure-related ischemic stroke occurred in approximately 1% of cases 5
A significant learning curve exists—complication rates decrease substantially with operator experience. 1, 6
Long-term Concerns:
- Device-related thrombus formation: up to 7.2% per year, associated with increased stroke risk 1
- Incomplete occlusion and peri-device leak remain unresolved issues 7
Post-Procedural Anticoagulation Requirements
A critical caveat: The device requires dual antiplatelet therapy (DAPT) for at least 6 weeks post-procedure, potentially exposing patients to bleeding risk—the very complication it aims to avoid. 1
Standard post-implantation regimen from trials 5:
- Warfarin for at least 45 days
- Aspirin plus clopidogrel from documented LAA closure until 6 months
- Aspirin alone thereafter
This requirement is problematic because patients with absolute contraindications to anticoagulation (the ideal candidates) were excluded from the pivotal trials 2, 5.
Critical Limitations
No randomized trials compare the Watchman device to NOACs (novel oral anticoagulants), which are now preferred over warfarin for most AF patients. 1 This represents a major evidence gap, as the device was only proven non-inferior to warfarin, not to the current standard of care.
Patient Selection Algorithm
Consider Watchman device for:
- Non-valvular AF (excludes mechanical valves and moderate-to-severe mitral stenosis) 2
- Elevated stroke risk (CHA₂DS₂-VASc ≥3 per CMS criteria) 2
- Contraindication to long-term oral anticoagulation due to:
- Ability to tolerate short-term anticoagulation (45 days minimum) 2
Oral anticoagulation remains the preferred therapy for most patients with AF and elevated stroke risk. 2 The device should be reserved for those who are genuinely poor candidates for long-term anticoagulation, not as a first-line alternative for convenience.